BioLineRX Ltd. (IL:BLRX)
TASE:BLRX
Want to see IL:BLRX full AI Analyst Report?
BLRX Stock Chart & Stats
1.50
>-0.01(-6.00%)
At close: 4:00 PM EST
1.50
>-0.01(-6.00%)
Day’s Range― - ―
52-Week Range1.10 - 3.90
Previous CloseN/A
Volume20.50M
Average Volume (3M)4.64M
Market Cap
₪33.94M
Enterprise Value18.28M
Total Cash (Recent Filing)₪20.88M
Total Debt (Recent Filing)₪10.15M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
May 27, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding2,610,814,500
10 Day Avg. Volume5,813,402
30 Day Avg. Volume4,637,561
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.68
Price to Sales (P/S)9.69
P/FCF Ratio-1.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)₪1.50M
Bulls Say, Bears Say
Bulls Say
Partnership/licensing Revenue ModelA business model centered on collaborations, milestone payments and royalties provides durable non‑dilutive funding levers and de‑risks late‑stage costs. Long‑term partnerships let larger pharma fund pivotal trials and commercialization, preserving cash and accelerating scale without sole internal capex.
Improving Balance Sheet LeverageA more manageable leverage profile and equity exceeding debt improves financial flexibility and lowers near‑term credit risk. This structural improvement supports the company's ability to access capital or negotiate partner deals over months, extending runway while clinical programs advance.
Attractive Unit Economics (positive Gross Margin)Positive gross margins indicate underlying product or service economics can support profitable operations at scale. If revenue stabilizes, fixed cost absorption could drive meaningful margin improvement, making future commercialization and royalty streams more sustainable long term.
Bears Say
Structural UnprofitabilityConsistent net losses and negative margins limit internal capital generation and constrain strategic options. Over a multi‑month horizon, ongoing unprofitability increases dependence on external financing or partner milestones, raising dilution and execution risk for clinical advancement.
Persistent Cash BurnSustained negative operating and free cash flow forces reliance on external funding or partnerships to sustain R&D and trials. Even with some improvement in TTM, persistent burn reduces runway visibility and limits the company's ability to self‑fund pivotal studies or commercial launches.
Sharp Recent Revenue ContractionA steep, recent decline in TTM revenue undermines predictability for upcoming periods and can disrupt milestone timing and partner payments. Reduced top‑line visibility complicates budgeting and heightens the need for external financing, slowing progress on development and commercialization plans.
Bioline Rx News
BLRX FAQ
What was BioLineRX Ltd.’s price range in the past 12 months?
BioLineRX Ltd. lowest stock price was 1.10 and its highest was 3.90 in the past 12 months.
What is BioLineRX Ltd.’s market cap?
BioLineRX Ltd.’s market cap is ₪33.94M.
When is BioLineRX Ltd.’s upcoming earnings report date?
BioLineRX Ltd.’s upcoming earnings report date is May 27, 2026 which is in 26 days.
How were BioLineRX Ltd.’s earnings last quarter?
BioLineRX Ltd. released its earnings results on Mar 23, 2026. The company reported 0 earnings per share for the quarter, beating the consensus estimate of -0.295 by 0.295.
Is BioLineRX Ltd. overvalued?
According to Wall Street analysts BioLineRX Ltd.’s price is currently Overvalued.
Does BioLineRX Ltd. pay dividends?
BioLineRX Ltd. does not currently pay dividends.
What is BioLineRX Ltd.’s EPS estimate?
BioLineRX Ltd.’s EPS estimate is -0.59.
How many shares outstanding does BioLineRX Ltd. have?
BioLineRX Ltd. has 2,610,814,500 shares outstanding.
What happened to BioLineRX Ltd.’s price movement after its last earnings report?
BioLineRX Ltd. reported an EPS of 0 in its last earnings report, beating expectations of -0.295. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of BioLineRX Ltd.?
Currently, no hedge funds are holding shares in IL:BLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioLineRX Ltd.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.